Olmecor Hct (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmecor Hct combines an ARB with a thiazide diuretic to treat hypertension through complementary mechanisms.

• Hypertension: helps achieve target blood pressure when monotherapy is insufficient.
• High‑risk cardiovascular patients: reduces the risk of stroke and heart attack as part of a comprehensive treatment plan.
• Edema associated with hypertension: promotes fluid excretion while controlling blood pressure.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary water excretion. Together, they lower systemic vascular resistance and plasma volume, producing an additive antihypertensive effect.

Olmecor Hct may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia or severe electrolyte imbalance
• Angio‑edema involving the face, lips or tongue
• Liver function abnormalities
• Blood dyscrasias such as agranulocytosis

Before initiating Olmecor Hct, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess creatinine and eGFR before and during therapy.
• Electrolytes: monitor potassium and sodium levels regularly.
• Volume status: watch for signs of dehydration or excessive fluid loss.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Concomitant drugs: review for potential interactions, especially other antihypertensives.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmecor Hct can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension and renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyper‑kalemia.
• Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect kidney function.
• Antidiabetic agents: may require dose adjustment due to enhanced glucose‑lowering effect.
• Corticosteroids: can increase sodium retention, counteracting diuretic action.